🟢 Merck is trading 5.6% up today after earnings beat and higher 2026 profit guidance

Merck is trading 5.6% higher at $148.79 after reporting third-quarter results on October 29 that exceeded analyst expectations.

• Third-quarter revenue was $18.1 billion and adjusted EPS was $2.49; Keytruda sales reached $8.6 billion.
• Winrevair sales grew 93% to $694 million.
• Merck raised 2026 adjusted EPS outlook to $2.77–$2.82 from $2.66–$2.76 and increased the low end of its sales forecast to $66.8 billion.